About Profluent Bio
Profluent Bio is a company based in Berkeley (United States) founded in 2022 by Alexander Meeske and Ali Madani. Profluent Bio has raised $150 million across 3 funding rounds from investors including Spark Capital, Insight Partners and Air Street Capital. Profluent Bio offers products and services including OpenCRISPR and ProGen3. Profluent Bio operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Frontier Medicines, among others.
- Headquarter Berkeley, United States
- Founders Alexander Meeske, Ali Madani
- SectorsHealthcareTechnology
- Email••••••••
- Website profluent.bio
- Social LinkedIn
- Legal Name Profluent Bio Inc.
- Total Equity Funding$150M (USD)
in 3 rounds
- Latest Funding Round$106M (USD), Series B
Nov 2025
- InvestorsSpark Capital
& 7 more
Products & Services of Profluent Bio
Profluent Bio offers a comprehensive portfolio of products and services, including OpenCRISPR and ProGen3.
AI-designed editor for gene modification in biological applications
System for authoring proteins in medicine and agriculture
Funding Insights of Profluent Bio
Profluent Bio has successfully raised a total of $150M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $106 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150M
- Total Rounds 3
- Last Round Series B — $106M
- First Round $9M
(Jan 2023)
- Investors Count 8
All 3 funding rounds of Profluent Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $106M | Series B | – | Altimeter Capital, Bezos Expeditions | |
| Mar 2024 | $35M | Series A | – | Spark Capital | |
| Jan 2023 | $9M | Seed | – | Insight Partners |
8 investors in total: 8 institutional.
Investors in Profluent Bio
Profluent Bio has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Spark Capital, Insight Partners and Air Street Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Spark Capital is engaged in venture capital investments. | – | sparkcapital.com | San Francisco, United States | |
Investment firm scaling software and technology companies from early to late stages. | – | insightpartners.com | - | |
Venture capital firm investing in AI & life science sectors | – | airstreet.com | St. Peter Port, United Kingdom | |
Venture capital is provided to AI-powered companies by AIX Ventures. | – | aixventures.com | Palo Alto, United States | |
Venture capital firm funding transformative technologies | – | phoenix-vp.com | San Mateo, United States | |
Early-stage investments are made in health and sustainability technologies. | – | convergentvc.com | - | |
Long/short equity hedge fund and VC fim | – | altimeter.com | - | |
Investment management and philanthropic ventures linked to Bezos Expeditions. | – | bezosexpeditions.com | - |
Investor details for Profluent Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Profluent Bio
13 people are tracked at Profluent Bio (5 in leadership, 8 in team).
| Name | Role | Group |
|---|---|---|
Alexander Meeske | Co-Founder | Leadership |
Ali Madani | Co-Founder & CEO | Leadership |
Hilary Eaton | Chief Business Officer | Leadership |
Joseph Gallagher | Associate Director | Leadership |
Jeffrey Ruffolo | Head Of Protein Design | Leadership |
Yasmeen Kaddoura | Sr. Operations Manager | Team |
Peter Cameron | Svp, Gene Editing And Translation | Team |
Michael R. Martyn III | Senior Software Engineer | Team |
Aadyot Bhatnagar | Machine Learning Scientist | Team |
Jennifer Yip | Associate Scientist | Team |
Jordan Russ | Associate Scientist | Team |
Riffat Hussain | Sr. Research Associate | Team |
Joel Beazer | Machine Learning Engineer | Team |
Complete people profiles for Profluent Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Profluent Bio
3 dated milestones of Profluent Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Profluent Bio is founded.
- Funding First funding round of $9.0M.
- Funding Latest funding round, Series B, of $106.0M.
Competitors of Profluent Bio
Profluent Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Frontier Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| cradle.bio | 2021 | Delft, Netherlands | $102.71M | – | Chemoproteomics solutions are provided for protein design and development. | |
| evolutionaryscale.ai | 2023 | New York, United States | $142M | – | Provider of an AI models for protein design | |
| evozyne.com | 2020 | Chicago, United States | $144.37M | – | Developer of proteins using protein engineering technology | |
| frontiermeds.com | 2018 | San Francisco, United States | $235.5M | 115 | Bioinformatics platform is developed for drug discovery and chemoproteomics. | |
| eikontx.com | 2019 | Hayward, United States | $1.16B | – | Protein dynamics are tracked and measured for drug discovery processes. | |
| entactbio.com | 2022 | Watertown, United States | $120.9M | – | Drugs are developed to enhance functions of beneficial proteins. |
Detailed competitors of Profluent Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Profluent Bio
The website of Profluent Bio (profluent.bio) receives about 23K visits a month.
- Monthly visits23K
▲ 32.1% vs previous month
Websites whose visitors overlap most with Profluent Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
genengnews.com | genengnews.com | 100% | – | #281,744 | – |
| nature.com | 86% | 33.6M | #1,922 | View details | |
| arxiv.org | 66% | 24.2M | #2,532 | View details |
Latest news on Profluent Bio
Complete news archive for Profluent Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Profluent Bio
10 companies that operate in the same segment as Profluent Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Profluent Bio
Profluent Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Profluent Bio is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Ali Madani is the current CEO of Profluent Bio. They have also founded this company.
Profluent Bio is a funded company, having raised a total of $150M across 3 funding rounds to date. The company's 1st funding round was a Seed of $9M, raised on Jan 2023.
Profluent Bio was founded in 2022 in Berkeley, United States. An artificial intelligence platform for protein design is offered within the biotechnology sector. Deep generative models are employed to create novel proteins with functional properties suitable for drug discovery applications. Operations center on advancing protein engineering techniques through computational methods, supporting research and development in therapeutics.
Profluent Bio's top competitors include Nimbus Therapeutics, Cradle and Eikon.
Profluent Bio offers OpenCRISPR and ProGen3.
Profluent Bio has 8 investors. Key investors include Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Phoenix Venture Partners.
Profluent Bio operates through Profluent Bio Inc..